APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biologics Monoclonal Antibodies Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologics Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026

Report ID 173970760421 December 2025197 pages

Choose your research edition.

Industry ResearchBiologics Monoclonal Antibodies Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics Monoclonal Antibodies Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Biologics Monoclonal Antibodies Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Biologics Monoclonal Antibodies Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologics Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologics Monoclonal Antibodies Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologics Monoclonal Antibodies Drug market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biologics Monoclonal Antibodies Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics Monoclonal Antibodies Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics Monoclonal Antibodies Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biologics Monoclonal Antibodies Drug market.

Biologics Monoclonal Antibodies Drug Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Biogen

Amgen

AbbVie

Sobi

Innovent Biologics

Biologics Monoclonal Antibodies Drug Segment by Type

Trastuzumab

Rituximab

Infliximab

Adalimumab

Other

Biologics Monoclonal Antibodies Drug Segment by Application

Cancer

Autoimmune Disease

Other

Biologics Monoclonal Antibodies Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologics Monoclonal Antibodies Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biologics Monoclonal Antibodies Drug key companies, revenue, market share, and recent developments.

3. To split the Biologics Monoclonal Antibodies Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biologics Monoclonal Antibodies Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologics Monoclonal Antibodies Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Biologics Monoclonal Antibodies Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics Monoclonal Antibodies Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics Monoclonal Antibodies Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics Monoclonal Antibodies Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics Monoclonal Antibodies Drug industry.

Chapter 3: Detailed analysis of Biologics Monoclonal Antibodies Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biologics Monoclonal Antibodies Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biologics Monoclonal Antibodies Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologics Monoclonal Antibodies Drug Industry Trends Table 2. Biologics Monoclonal Antibodies Drug Industry Drivers Table 3. Biologics Monoclonal Antibodies Drug Industry Opportunities and Challenges Table 4. Biologics Monoclonal Antibodies Drug Industry Restraints Table 5. Global Biologics Monoclonal Antibodies Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologics Monoclonal Antibodies Drug Revenue Share by Company (2021-2026) Table 7. Global Biologics Monoclonal Antibodies Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biologics Monoclonal Antibodies Drug Key Company Manufacturing Base & Headquarters Table 9. Global Biologics Monoclonal Antibodies Drug Company, Product Type & Application Table 10. Global Biologics Monoclonal Antibodies Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biologics Monoclonal Antibodies Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Trastuzumab Table 15. Significant Companies of Rituximab Table 16. Significant Companies of Infliximab Table 17. Significant Companies of Adalimumab Table 18. Significant Companies of Other Table 19. Global Biologics Monoclonal Antibodies Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Biologics Monoclonal Antibodies Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Biologics Monoclonal Antibodies Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Type (2021-2026) Table 23. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Cancer Table 25. Significant Companies of Autoimmune Disease Table 26. Significant Companies of Other Table 27. Global Biologics Monoclonal Antibodies Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biologics Monoclonal Antibodies Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Biologics Monoclonal Antibodies Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Application (2021-2026) Table 31. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Application (2027-2032) Table 32. Global Biologics Monoclonal Antibodies Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Biologics Monoclonal Antibodies Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Region (2021-2026) Table 35. Global Biologics Monoclonal Antibodies Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Region (2027-2032) Table 37. Global Biologics Monoclonal Antibodies Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Biologics Monoclonal Antibodies Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Biologics Monoclonal Antibodies Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Biologics Monoclonal Antibodies Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Biologics Monoclonal Antibodies Drug Sales Value Market Share by Country (2027-2032) Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi Biologics Monoclonal Antibodies Drug Product Portfolio Table 46. Sanofi Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Johnson & Johnson Biologics Monoclonal Antibodies Drug Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Novartis Company Information Table 53. Novartis Business Overview Table 54. Novartis Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Novartis Biologics Monoclonal Antibodies Drug Product Portfolio Table 56. Novartis Recent Development Table 57. Merck Company Information Table 58. Merck Business Overview Table 59. Merck Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Merck Biologics Monoclonal Antibodies Drug Product Portfolio Table 61. Merck Recent Development Table 62. Roche Company Information Table 63. Roche Business Overview Table 64. Roche Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Roche Biologics Monoclonal Antibodies Drug Product Portfolio Table 66. Roche Recent Development Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Eli Lilly Biologics Monoclonal Antibodies Drug Product Portfolio Table 71. Eli Lilly Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Pfizer Biologics Monoclonal Antibodies Drug Product Portfolio Table 76. Pfizer Recent Development Table 77. Biogen Company Information Table 78. Biogen Business Overview Table 79. Biogen Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Biogen Biologics Monoclonal Antibodies Drug Product Portfolio Table 81. Biogen Recent Development Table 82. Amgen Company Information Table 83. Amgen Business Overview Table 84. Amgen Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Amgen Biologics Monoclonal Antibodies Drug Product Portfolio Table 86. Amgen Recent Development Table 87. AbbVie Company Information Table 88. AbbVie Business Overview Table 89. AbbVie Biologics Monoclonal Antibodies Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AbbVie Biologics Monoclonal Antibodies Drug Product Portfolio Table 91. AbbVie Recent Development Table 92. Sobi Company Information Table 93. Sobi Business Overview Table 94. Sobi Biologics Monoclonal Antibodies Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Sobi Biologics Monoclonal Antibodies Drug Product Portfolio Table 96. Sobi Recent Development Table 97. Innovent Biologics Company Information Table 98. Innovent Biologics Business Overview Table 99. Innovent Biologics Biologics Monoclonal Antibodies Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Innovent Biologics Biologics Monoclonal Antibodies Drug Product Portfolio Table 101. Innovent Biologics Recent Development Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Biologics Monoclonal Antibodies Drug Product Image Figure 2. Global Biologics Monoclonal Antibodies Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics Monoclonal Antibodies Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics Monoclonal Antibodies Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Trastuzumab Image Figure 8. Rituximab Image Figure 9. Infliximab Image Figure 10. Adalimumab Image Figure 11. Other Image Figure 12. Global Biologics Monoclonal Antibodies Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Biologics Monoclonal Antibodies Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Type (2021-2032) Figure 15. Cancer Image Figure 16. Autoimmune Disease Image Figure 17. Other Image Figure 18. Global Biologics Monoclonal Antibodies Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biologics Monoclonal Antibodies Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Application (2021-2032) Figure 21. Global Biologics Monoclonal Antibodies Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Biologics Monoclonal Antibodies Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Biologics Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Biologics Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Biologics Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Biologics Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Biologics Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Biologics Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Biologics Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Biologics Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Biologics Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Biologics Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Trastuzumab
  • Rituximab
  • Infliximab
  • Adalimumab
  • Other
Applications
  • Cancer
  • Autoimmune Disease
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Biogen
  • Amgen
  • AbbVie
  • Sobi
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologics Monoclonal Antibodies Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologics Monoclonal Antibodies Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biologics Monoclonal Antibodies Drug Market Dynamics
  1. 2.1 Biologics Monoclonal Antibodies Drug Industry Trends
  2. 2.2 Biologics Monoclonal Antibodies Drug Industry Drivers
  3. 2.3 Biologics Monoclonal Antibodies Drug Industry Opportunities and Challenges
  4. 2.4 Biologics Monoclonal Antibodies Drug Industry Restraints
3 Biologics Monoclonal Antibodies Drug Market by Company
  1. 3.1 Global Biologics Monoclonal Antibodies Drug Company Revenue Ranking in 2025
  2. 3.2 Global Biologics Monoclonal Antibodies Drug Revenue by Company (2021-2026)
  3. 3.3 Global Biologics Monoclonal Antibodies Drug Company Ranking (2024-2026)
  4. 3.4 Global Biologics Monoclonal Antibodies Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Biologics Monoclonal Antibodies Drug Company Product Type and Application
  6. 3.6 Global Biologics Monoclonal Antibodies Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biologics Monoclonal Antibodies Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biologics Monoclonal Antibodies Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biologics Monoclonal Antibodies Drug Market by Type
  1. 4.1 Biologics Monoclonal Antibodies Drug Type Introduction
  2. 4.1.1 Trastuzumab
  3. 4.1.2 Rituximab
  4. 4.1.3 Infliximab
  5. 4.1.4 Adalimumab
  6. 4.1.5 Other
  7. 4.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Type
  8. 4.2.1 Global Biologics Monoclonal Antibodies Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global Biologics Monoclonal Antibodies Drug Sales Value Share by Type (2021-2032)
5 Biologics Monoclonal Antibodies Drug Market by Application
  1. 5.1 Biologics Monoclonal Antibodies Drug Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Autoimmune Disease
  4. 5.1.3 Other
  5. 5.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Application
  6. 5.2.1 Global Biologics Monoclonal Antibodies Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Biologics Monoclonal Antibodies Drug Sales Value Share by Application (2021-2032)
6 Biologics Monoclonal Antibodies Drug Regional Value Analysis
  1. 6.1 Global Biologics Monoclonal Antibodies Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biologics Monoclonal Antibodies Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologics Monoclonal Antibodies Drug Sales Value (2021-2032)
  7. 6.3.2 North America Biologics Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biologics Monoclonal Antibodies Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Biologics Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biologics Monoclonal Antibodies Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biologics Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biologics Monoclonal Antibodies Drug Sales Value (2021-2032)
  16. 6.6.2 South America Biologics Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biologics Monoclonal Antibodies Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biologics Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
7 Biologics Monoclonal Antibodies Drug Country-level Value Analysis
  1. 7.1 Global Biologics Monoclonal Antibodies Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biologics Monoclonal Antibodies Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biologics Monoclonal Antibodies Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biologics Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biologics Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biologics Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Biologics Monoclonal Antibodies Drug Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Biologics Monoclonal Antibodies Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biologics Monoclonal Antibodies Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Biologics Monoclonal Antibodies Drug Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Biologics Monoclonal Antibodies Drug Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Biologics Monoclonal Antibodies Drug Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Biologics Monoclonal Antibodies Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Biogen
  44. 8.8.1 Biogen Company Information
  45. 8.8.2 Biogen Business Overview
  46. 8.8.3 Biogen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biogen Biologics Monoclonal Antibodies Drug Product Portfolio
  48. 8.8.5 Biogen Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Biologics Monoclonal Antibodies Drug Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Biologics Monoclonal Antibodies Drug Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 Sobi
  62. 8.11.1 Sobi Company Information
  63. 8.11.2 Sobi Business Overview
  64. 8.11.3 Sobi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sobi Biologics Monoclonal Antibodies Drug Product Portfolio
  66. 8.11.5 Sobi Recent Developments
  67. 8.12 Innovent Biologics
  68. 8.12.1 Innovent Biologics Company Information
  69. 8.12.2 Innovent Biologics Business Overview
  70. 8.12.3 Innovent Biologics Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Innovent Biologics Biologics Monoclonal Antibodies Drug Product Portfolio
  72. 8.12.5 Innovent Biologics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst